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Introduction: Recent work has shown that benzodiazepines interact with the immune system and exhibit
anti-inflammatory effects. By using in vitro models, researchers in several studies have shown that the peptidergic
endogenous ligands of benzodiazepine receptors, named endozepines, are involved in the immune response. All
endozepines identified so far derive from diazepam-binding inhibitor (DBI), which generates several biologically
active fragments. The aim of the present study was to measure plasma levels of DBI-like immunoreactivity (DBI-LI)
in a rat model of sepsis and in patients with systemic inflammation from septic or non-septic origin.
Methods: Cecal ligation and puncture (CLP) or sham surgery was performed in rats. Blood samples were taken from
animals, patients hospitalized for digestive surgery with inflammatory diseases, and healthy volunteers. Measurements
of plasma DBI-related peptides were carried out by radioimmunoassay in animal and human samples.
Results: In the rats, CLP provoked an increase of plasma DBI-LI (+37%) 6 hours postsurgery. In humans, DBI-LI levels
were significantly higher in the systemic inflammation group than in the healthy volunteer group (48.6 (32.7 to 77.7)
pg/ml versus 11.1 (5.9 to 35.3) pg/ml, P < 0.001). We found a positive correlation between endozepine levels and Acute
Physiology and Chronic Health Evaluation II score (rs = 0.33 (0.026 to 0.58), P < 0.05) and tumor necrosis factor α levels
(rs = 0.43 (0.14 to 0.65), P < 0.01). The area under the receiver operating characteristic curve for endozepines was 0.842
(95% CI (0.717 to 0.966), P < 0.0001) for discriminating patients with inflammation from healthy volunteers.
Conclusions: Endozepines might be involved in the inflammatory response in patients with systemic inflammation.Introduction
Benzodiazepines are currently the most widely used
drugs for prolonged sedation in intensive care units
(ICUs) [1]. Nevertheless, the results of studies performed
in animal models and humans suggest that prolonged
treatment with benzodiazepines could increase mortality
related to sepsis [2,3]. Accordingly, beyond their sedative* Correspondence: vincent.compere@chu-rouen.fr
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unless otherwise stated.effects, benzodiazepines also seem to have anti-inflammatory
effects due to their interaction with the innate immune [4].
Sedative and/or hypnotic effects of benzodiazepines are
mediated through type A γ-aminobutyric acid (GABAA)
receptors, a chloride channel mainly expressed in the
central nervous system (CNS) that exhibits benzodiazep-
ine binding sites, named central-type benzodiazepine re-
ceptors (CBR) [5]. In contrast to CBR, peripheral-type
benzodiazepine receptors, now renamed translocator pro-
tein (TSPO), are mitochondrial receptors coupled to an
anion channel, mostly—but not only—located in per-
ipheral tissues [6]. Thus, although they likely bind the
same benzodiazepine ligands, potentiation of the activity ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ition in CNS, whereas TSPO, which is broadly expressed in
various organs (heart, kidney, liver, lung, adrenal glands)
and cells (platelets, lymphocytes, mononuclear cells, endo-
thelium, vascular smooth muscle, mast cells), may play a
role in immune function and inflammation regulation [7,8].
The term endozepines designates a family of neuropep-
tides originally isolated from the rat brain as endogenous
ligands of benzodiazepine receptors [9]. All endozepines
derive from the polypeptide diazepam-binding inhibitor
(DBI), generating through proteolytic cleavage of several
biologically active peptides, including the octadecaneuro-
peptide DBI33–50 (ODN) [10]. Endozepines exert some of
their effects through classical benzodiazepine receptors
(that are, CBR and TSPO). DBI and ODN, which are both
able to interact with CBR and to exert the inverse effects
of benzodiazepines, are considered inverse agonists of this
receptor. DBI is also considered an endogenous TSPO
agonist; for example, DBI stimulates mitochondrial ste-
roidogenesis through TSPO activation [9-11]. Endozepines
are widely distributed in tissues and organs, notably in
immune tissues (lymphocytes and monocytes), and
the results of in vitro studies suggest an involvement
of endozepines in cellular immune responses [12,13]. In
particular, endozepines have been shown to (1) enhance
lipopolysaccharide (LPS)-induced expression of tumor
necrosis factor α (TNF-α), interleukin 1β (IL-1β) and
interleukin 6 (IL-6) [14,15], and (2) stimulate chemotaxis,
superoxide anion production and phagocytosis in isolated
human neutrophils [16]. The prevention of immunosup-
pressive effects of benzodiazepines by a specific TSPO
antagonist suggests that the anti-inflammatory effect of
benzodiazepines is, at least in part, relayed by these recep-
tors and that endogenous ligands of TSPO may play a role
in inflammatory pathophysiological processes [17].
The function of endozepines during inflammation and
sepsis remains unknown and knowledge concerning
its secretion in blood during systemic inflammatory
responses is lacking. We hypothesized that endozepines
could be enhanced during systemic inflammation and
sepsis because of their interaction with immune response.
Thus, this study focused on the measurement of plasma




Sprague–Dawley male rats (Charles River, Elbeuf, France)
weighing 200 to 250 g were housed under a constant
temperature (21°C) in a 14-hr/10-hr light/dark cycle. The
protocol was approved by the North-West Regional Ethic
Committee on Animal Experimentation in France (referral
number ceean0406-01, approval number 01-04-06/03).Sepsis was induced by cecal ligation and puncture (CLP)
as previously described [18]. Rats were anesthetized with
ketamine (80 mg/kg) and xylazine (10 mg/kg). A 2-cm
midline incision was made; the cecum was ligated below
the ileocecal valve and punctured twice with an 18-gauge
needle; and squeezed. The cecum was then placed back
into the abdomen, and the incision was sutured. For
sham-operated control rats, the cecum was exposed but
was not ligated or punctured. The rats were killed by
decapitation 1, 2, 3, 4, 6, 12 and 24 hours after surgery
(5 animals/group for each time slot); trunk blood was
collected in dried tubes; and the serum was obtained
by centrifugation. Samples were stored at −80°C until
endozepine extraction and radioimmunoassay (RIA).
Clinical human protocol
Population studied
This study was conducted at the Rouen University Hospital
from December 2006 to December 2009. It had been
approved by the institutional review board (North-West
Research Ethics Committee, Rouen University Hospital,
France, referral number 2005/017) and therefore was
performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its
later amendments.
Patients admitted to the digestive surgery unit with sys-
temic inflammation were included. Exclusion criteria for pa-
tients with inflammation and healthy volunteers were age
under 18 years or patient under tutorship, imprisoned in-
mates, pregnancy, participation in another clinical study,
patient refusal and treatment with benzodiazepines within
3 months prior to inclusion. Patients were included in two
groups after they provided their informed consent to partici-
pate: (1) healthy volunteers from the clinical investigation
center and (2) patients with nonseptic inflammation or sep-
sis as defined by the Society of Critical Care Medicine [19].
The data collected included demographic characteristics,
length of hospitalization, Acute Physiology and Chronic
Health Evaluation II (APACHE II) score, biological levels
of inflammatory markers (C-reactive protein (CRP),
procalcitonin (PCT), TNF-α, IL-1β and IL-6).
Sampling
Samples taken during the patient’s hospitalization were
scheduled between 8:00 AM and 9:00 AM because of
the possible existence of a circadian rhythm influen-
cing the release of endozepines. Blood was centrifuged
(10 minutes at 3,000 g and 4°C), and serum samples were
stored at −80°C until endozepine extraction and RIA.
Endpoints
The primary endpoint was the comparison of plasma
endozepine levels between patients with inflammation
and healthy volunteers. Secondary endpoints included
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other markers of inflammation, (2) assessment of potential
correlations between endozepine levels and APACHE II
scores and markers of inflammation and (3) determination
of an endozepine level threshold that would enable us
to discriminate healthy volunteers from patients with
inflammation.Radioimmunoassay of endozepines (diazepam-binding
inhibitor–like immunoreactivity) in rat and human plasma
Serum samples (rat: 1 ml, human: 2 ml) were diluted
with 0.1% trifluoracetic acid (vol/vol) and heated at 56°C
for 20 minutes. After centrifugation (3,200 g for 20 minutes
at 4°C), peptides contained in the surpernatant were con-
centrated on Sep-Pak C18 cartridges (Alltech Europe,
Lokeren Belgium). Bound material was eluted with 50%
(vol/vol) acetonitrile/water containing 0.1% trifluoracetic
acid (vol/vol), and the solvent was evaporated by vacuum
centrifugation (Savant SpeedVac Concentrator; Thermo
Scientific, Hicksville, NY, USA). The dry samples were
resuspended in phosphate buffer (0.1 M, pH 8) containing
0.1% Triton X-100, and the concentrations of DBI-LI were
quantified by RIA using antisera raised against synthetic
rat DBI33–50 (rDBI33–50, QATVGDVNTDRPGLLDLK)
or synthetic human DBI33–50 (hDBI33–50, QATVGDINTE
RPGMLDFT) (PolyPeptide Group, Strasbourg, France) in
rabbit, as previously described [20]. Briefly, [Tyr0]-rDBI33–50
and [Tyr0]-hDBI33–50 were iodinated using the chloramine-
T procedure and purified on a Sep-Pak C18 cartridge. The
final dilutions of the antisera were 1:30,000 (rDBI33–50
antibodies) and 1:15,000 (hDBI33–50 antibodies). The total
amount of 125I[Tyr0]-rDBI33–50 and
125I[Tyr0]-hDBI33–50
was 6,000 counts per minute for each tube. After a 2-day
incubation at 4°C, the antibody-bound DBI-related fraction
was precipitated by adding bovine γ-globulins (1%, wt/vol,
100 μl) and polyethylene glycol 8000 (20%, wt/vol, 2 ml).
After centrifugation, the pellet containing the bound
fraction was counted in a gamma counter (LKB Wallac,
Rockville, MD, USA). Antibodies against rDBI33–50 and
hDBI33–50 (ODN), respectively, detected the rat or
human form of DBI [21,22]. Thus, rDBI33–50 and
hDBI33–50 antibodies were not strictly specific for
ODN and likely revealed the presence of DBI-related
species in plasma.Measurement of inflammatory markers in human plasma
IL-6 was measured with an immunochemiluminescence
assay (IMMULITE 2500; Siemens Medical Systems,
Los Angeles, CA, USA). TNF-α and IL-1β levels were
measured by enzyme-linked immunosorbent assays:
Human TNF-α Ready-SET-Go kit (eBioscience, San Diego,
CA, USA) and Human IL-1β Quantikine kit (R&D Systems,
Minneapolis, MN, USA).Statistical analysis
Our presently reported work is an observational pilot
study in which we investigated, for the first time to our
knowledge, plasma levels of endozepines in patients with
inflammation. Therefore, we did not establish an a priori
calculation of the number of subjects required, but the
inclusion of patients was performed to achieve a statistical
power greater than 90% for nonparametric tests.
Values presented in the text and figures are median
with 25th to 75th interquartile range or average with
standard deviation. The Mann–Whitney U test was
applied to determine statistical differences (α risk of 5%,
β risk of 20%). Correlation was tested using Spearman’s
rank correlation coefficient (rs). Receiver operating charac-
teristic (ROC) curve analysis, including area under the
ROC curve (AUC), was used to determine an endozepine
level threshold able to discriminate groups. Samples whose
endozepine level was below the minimum detection
threshold of the assay were excluded from the statistical
analysis because of the impossibility of assessing the primary
endpoint. Subjects with unmeasurable endozepine levels
were compared to those with measurable levels by using
Fisher’s exact test. Statistics were calculated using GraphPad
Prism software (GraphPad Software, La Jolla, CA, USA).
Results
Preclinical evaluation of endozepines in rat plasma during
sepsis
Time-course experiments over a period of 24 hours
revealed that CLP provoked a time-dependent increase in
DBI-LI peptide concentrations in plasma. This increase
was statistically significant after a 6-hour period (+37%;
P < 0.05) and reached a plateau at 12 hours (Figure 1).
Clinical evaluation of endozepines in plasma of patients
Epidemiologic characteristics
Sixty-seven subjects were included during the study
period: forty-four in the group of patients with inflam-
mation and twenty-three in the healthy volunteer group.
There were no significant differences regarding age, weight
or sex ratios between healthy volunteers and patients
(Table 1). Patients with inflammation had appendicular
peritonitis (n = 13), appendicular abscess (n = 3), cholangitis
(n = 7), biliary peritonitis (n = 3), acute pancreatitis (n = 10),
acute cholecystitis (n = 3) or sigmoid perforation (n = 5).
Endozepine, biomarkers of inflammation and creatinine
levels in patients with inflammation and in healthy
volunteers
Endozepine levels were not detected in seven samples
taken from the healthy volunteer group. The number of
patients with an unmeasurable level of endozepines was
significantly higher in the healthy volunteer group than
in the patient group (7 vs 0, P < 0.01). In the healthy
Figure 1 Time course of the effect of cecal ligation and puncture on diazepam-binding inhibitor–like immunoreactivity in rat plasma.
Diazepam-binding inhibitor–like immunoreactivity (DBI-LI) was measured at the times indicated, after surgery, in the sera of sham-operated
(SHAM, open circles) and cecal ligation and puncture (CLP, filled circles) animals (n = 5 animals/group for each time slot; each value represents
the mean (± SEM) calculated from 5 animals). *P < 0.05 by Mann–Whitney U test; ns: not statistically different vs. SHAM.
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between the “endozepine measurable” subgroup (n = 16)
and the “endozepine undetectable” subgroup (n = 7) on
the variables age, weight, sex ratio and plasma levels of
TNF-α. The number of patients included in each group
for statistical analysis and the distribution of endozepine
levels provided a statistical power for nonparametric tests
of 99%. The DBI-LI levels were significantly higher in the
group of patients with inflammation than in the
healthy volunteer group (48.6 [32.7 to 77.7] pg/ml vs 11.1Table 1 Epidemiologic characteristics, endozepine,
biomarkers of inflammation and cytokine levels of




inflammation (n = 44)
Age (yr) 37.0 [29 to 45] 44 [28 to 60]b
Sex, n (M/F) 8/8b 23/21
Weight (kg) 61 [59.5 to 71] 71 [62 to 80]b
APACHE II score NA 3 [2–6]
Length of stay (days) NA 5 [4–8]
Creatinine (μmol/L) UM 72 [61 to 79]
DBI-LI (pg/ml) 11.1 [5.9 to 35.3] 48.6 [32.7 to 77.7]c
PMN (×103/ml) UM 9.2 [6.7 to 13]
CRP (mg/L) UM 189 [132 to 279]
PCT (μg/L) UM 0.25 [0.16 to 1.4]
TNF-α (pg/ml) 6.1 [3.1 to 13.7] 4.2 [2.9 to 5.7]b
IL-1β (pg/ml) UD 0.37 [0.12 to 0.69]
IL-6 (pg/ml) UD 48.7 [17.6 to 79.7]
aThe results are expressed as median and 25th to 75th interquartile range.
bNot statistically different from healthy volunteers; cP < 0.001 vs healthy
volunteers. APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP,
C-reactive protein, DBI-LI, Diazepam-binding inhibitor–like immunoreactivity; IL,
Interleukin; NA, Not applicable, PCT, Procalcitonin; PMN, Polymorphonuclear
neutrophils; TNF-α, Tumor necrosis factor α; UM, Unmeasured; UD, Undetectable.[5.9 to 35.3] pg/ml, P < 0.001) (Table 1). All healthy volun-
teers had undetectable levels of IL-1β and IL-6. There was
no difference of TNF-α levels between groups (Table 1).
When we studied patients with inflammation (n = 44),
endozepine levels did not significantly correlate with
IL-6, IL-1β, PCT and CRP levels (Table 2). However,
there was a positive correlation between endozepine
levels and APACHE II score (rs = 0.33 [0.026 to 0.58],
P < 0.05) (Figure 2a) and TNF-α levels (rs = 0.43 [0.14
to 0.65], P < 0.01) (Figure 2b). When we studied patients
with inflammation with an APACHE II score ≥ 6 (n = 12),
we detected a positive correlation between endozepine and
CRP levels (rs = 0.78 [0.35 to 0.94], P < 0.01). We noticed
that, in this subgroup, no correlation between endozepine
levels and TNF-α, IL-6, IL-1β, PCT levels or APACHE II
score was found (data not shown).
Discriminative level of endozepine between patients with
inflammation and healthy volunteers
With regard to endozepines, the AUC for discriminating
systemic patients with inflammation from healthy volun-
teers was 0.842 (95% CI, 0.717 to 0.966; P < 0.0001). WithTable 2 Correlation of endozepine levels with biomarkers
of inflammationa
Biomarker or APACHE II score Spearman’s rank correlation
IL-6 0.16 [−0.15 to 0.45]
IL-1β −0.15 [−0.44 to 0.17]
TNF-α 0.43 [0.14 to 0.65]b
CRP 0.10 [−0.22 to 0.41]
PCT 0.089 [−0.26 to 0.42]
APACHE II score 0.33 [0.026 to 0.58]c
aCRP, C-reactive protein; IL, Interleukin; PCT, Procalcitonin; TNF-α, Tumor
necrosis factor α. bP < 0.01. cP < 0.05.
Figure 2 Correlations between plasma endozepine concentrations
and biomarkers of inflammation and Acute Physiology and
Chronic Health Evaluation II scores in patients with inflammation.
Graphs depict the significant positive correlation between plasma
endozepine levels and Acute Physiology and Chronic Health Evaluation
II (APACHE II) scores in patients with inflammation (a) and between
plasma endozepine levels and plasma tumor necrosis factor α (TNF-α) in
patients with inflammation (b). Correlation coefficients are Spearman’s
coefficients (rs) with 95% confidence intervals. The results are presented
as Log2 ratios. DBI-LI, Diazepam-binding inhibitor–like immunoreactivity.
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was 88.6% and the specificity was 68.8% (Figure 3).
Discussion
The present data show, for the first time to our knowledge,
that endozepine plasma levels are enhanced during sys-
temic inflammation in both rats and humans. The study
conducted in humans revealed that endozepine levels were
increased in patients with inflammation compared with
healthy volunteers.
Benzodiazepines are the most widely used drugs for
prolonged sedation in the ICU [1]. In vitro studies
suggested an immunosuppressive effect of benzodiazepines
through an inhibition of cytokine secretion, dendritic cell
antigen presentation or natural killer cell activity
[4,23,24]. Non-benzodiazepine-based sedation could re-
duce mortality in septic patients in comparison withsedation using lorazepam [3]. However, this difference
between benzodiazepine- and non-benzodiazepine-based
sedation was not found in a recent meta-analysis of a
general ICU population [25]. Thus, the impact of
benzodiazepines on morbidity and mortality related to
sepsis is still unclear. In this context, the characterization
of plasma level variations of the endogenous ligands of
benzodiazepine receptors, and raising their potential
role during inflammation and sepsis, would provide new
information on the potential side effects of benzodiazepine
sedation in the ICU and would help to determine a poten-
tial use of specific CBR or TSPO ligands in inflammatory
pathologies.
The results of the present study show that CLP
induced a significant increase of endozepine plasma
levels. These results led us to investigate the plasma
concentration of endozepines in patients with inflam-
mation and healthy volunteers. The concentrations of
endozepines detected in plasma of healthy volunteers
(11 [5.9 to 35.3] pg/ml in the present study) are of
the same order as that measured by RIA (16 ± 5.3 pg/ml)
in healthy controls of the same age in a previously
published study, suggesting that the method of plasma
endozepine detection used could be standardized within
other clinical centers [26].
Tissues and signals responsible for the increase of
endozepines in inflammatory subjects are currently
unknown. Numerous tissues and organs express the
DBI gene, and high levels of endozepines have been
notably detected in basal conditions in human brain,
liver, kidney, testis and adrenal glands [27,28]. Release
of endozepines from rat hypothalamic explants has re-
cently been demonstrated [29]. However, DBI mRNA
expression in peripheral tissues and the release of endoze-
pines from the intestine in rats suggest that the increase
of circulating endozepines may result from peripheral
organ release [27,28,30].
In our present study, measurement of cytokines in
plasma showed very low or undetectable levels of TNF-α
and IL-1β in all groups. This is consistent with the kinetics
of TNF-α production. No IL-1β increase during sepsis
was detected in other studies [31,32]. The positive
correlation between endozepine and TNF-α plasma
levels leads us to propose that the rise of plasma
endozepines in inflammation could be either a consequence
of overproduction of TNF-α or, conversely, a signal for
cytokine production. In agreement with this hypothesis, it
has been shown that the endozepine ODN potentiated the
LPS-induced secretion of IL-6 by human monocytes [15].
In addition, it has been found that triakontatetraneuropep-
tide, a DBI-related peptide, and ODN potentiate the effects
of LPS on the release of TNF-α and IL-1β by human
monocytes and could thus maintain the inflammatory
response [14,33]. The correlation between endozepines and
Figure 3 Receiver operator characteristic curve generated with plasma levels of endozepines in patients with systemic inflammation
and healthy volunteers. The receiver operator characteristic (ROC) curve is the plot of the true positive rate (sensitivity) vs the false positive rate
(100 − specificity) for different positivity thresholds (that is, different cutoff levels of endozepines). DBI-LI, Diazepam-binding inhibitor–like immunoreactivity.
The calculated value of the area under the ROC curve (AUC) was 0.842 (superior to the random value of 0.5), indicating that DBI-LI plasma discriminated
healthy volunteers from patients with systemic inflammation (P< 0.0001).
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CRP in patients with inflammation with an APACHE II
score ≥ 6 may also indicate that the increase of endozepines
could be correlated with inflammation severity. However,
given the low TNF-α concentration and the low overall
inflammation severity in our patients, correlation with
endozepine levels must be interpreted with caution.
Although these data suggest a link between cytokines and
endozepines, the connections between these two families
of compounds remain to be elucidated.
The increase of endozepine levels in inflammation
could have several consequences. In particular, TSPO
has been found in many cells and tissues, including
leukocytes such as macrophages and neutrophils, and
also in steroidogenic tissues such as the adrenal gland
[34]. These data suggest that TSPO could be a relevant
target for endozepines during inflammation and sepsis.
Besides this possible link between endozepines, TSPO and
inflammation, it has been shown that ODN is a potent
anorexigenic factor in rodents [35,36]. Thus, the increased
levels of endozepines could be involved in anorexia related
to acute inflammation. Moreover, in several in vitro
studies, researchers have shown that endozepines inhibit
glucose-stimulated release of insulin in rats, suggest-
ing that an increase of endozepine levels could con-
tribute to hyperglycemia induced by inflammation
[37]. Future study of a possible relationship between
endozepine, cortisol levels and glycemia during systemic
inflammation to explore these hypotheses would be
worthwhile.The presently reported data indicate that endozepines are
greatly increased in patients with inflammation, with an
AUC of 0.842 to discriminate patients with inflammation vs
healthy volunteers. Thus, the plasma endozepine level
appears as efficient as CRP and PCT levels for the diagnosis
of a biological systemic inflammatory response [38,39].
Nevertheless, the present work has several limitations. First,
it is a single-center study including a limited number
of patients, and only protocols including a larger
number of patients in each group could allow identification
of a stronger specific threshold. Second, the time of
collection relative to the natural history of the disease was
not standardized between patients. Such standardization
would have been quite difficult, given the heterogeneity
of the diseases included, but it will be necessary to
standardize this parameter in a future clinical protocol
including a large number of patients from various clinical
centers. In addition, several data have not been identified
at the time of sampling (for example, antibiotic therapy,
diabetes, temperature), and it would have been be
interesting to study the possible existence of a link
between these factors and endozepine level. Third, the
study design excluded patients with septic shock, and
then all septic patients included comprised a non-ICU
homogeneous population with abdominal infections
with low APACHE II scores. Most of the patients with
septic shock were sedated with benzodiazepines and, con-
sequently, were excluded from our study. Interferences
between exogenous benzodiazepines and endozepines
were unknown; thus, treatment with benzodiazepines was
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a recent study, investigators showed that repetitive
administration of diazepam stimulated DBI production in
rats [40]. Together, it can be assumed that (1) measurement
of plasma endozepines in this specific ICU population
should be considered, (2) development of a nonseptic
inflammatory model in rats should be suitable to highlight
differences in levels of endozepines between septic
and nonseptic inflammatory states and (3) variation of
the CLP model severity (for example, by varying the size
and/or number of cecal punctures) should be envisaged to
study a potential link between the severity of sepsis and
endozepine levels.
Conclusions
Altogether, the present data show, for the first time to our
knowledge, that plasma endozepines, endogenous ligands of
benzodiazepine receptors, are enhanced in the inflammatory
response in both rodents and humans. It would be interest-
ing to study plasma levels of endozepines during severe sep-
sis and septic shock to determine whether endozepines
could be proposed as a prognostic factor for serious infec-
tion, and also as a potential therapeutic target during septic
and nonseptic inflammation. In this context, the next part
of our work will consist of assessment of the endozepine
course in plasma of septic patients during hospitalization.
Key messages
 Endozepines, endogenous ligands of benzodiazepine
receptors involved in cellular immune responses, are
enhanced in the inflammatory response in humans.
 Tissues and signals responsible for this increase and
its consequences in patients with inflammation are
currently unknown and remain to be explored.
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